• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    2/14/23 12:37:55 PM ET
    $HUM
    Medical Specialities
    Health Care
    Get the next $HUM alert in real time by email
    SC 13G/A 1 hum13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) HUMANA INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 444859102 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 3,339,442 6. Shared Voting Power* 0 7. Sole Dispositive Power* 7,610,595 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 7,623,150 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 6.0% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: HUMANA INC Item 1(b) Address of Issuer's Principal Executive Offices: 500 W MAIN ST, LOUISVILLE, KENTUCKY 40202 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 444859102 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2022
    Get the next $HUM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HUM

    DatePrice TargetRatingAnalyst
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    11/6/2024$247.00 → $308.00Underperform → Neutral
    BofA Securities
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    10/8/2024$308.00Mkt Perform → Outperform
    Bernstein
    10/7/2024$402.00 → $261.00Buy → Hold
    TD Cowen
    10/7/2024$519.00 → $253.00Buy → Hold
    Jefferies
    10/3/2024$392.00 → $274.00Overweight → Neutral
    Piper Sandler
    10/2/2024$376.00 → $247.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Accting Off & Cont. Felter John-Paul W. converted options into 211 units of Humana Common and covered exercise/tax liability with 97 units of Humana Common, increasing direct ownership by 6% to 1,881 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    8/5/25 1:22:18 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Hilzinger Kurt J

    4 - HUMANA INC (0000049071) (Issuer)

    7/2/25 4:18:17 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Smith Gordon

    4 - HUMANA INC (0000049071) (Issuer)

    7/2/25 2:21:21 PM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    SEC Filings

    View All

    SEC Form 10-Q filed by Humana Inc.

    10-Q - HUMANA INC (0000049071) (Filer)

    7/30/25 3:37:58 PM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HUMANA INC (0000049071) (Filer)

    7/30/25 6:07:27 AM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 11-K filed by Humana Inc.

    11-K - HUMANA INC (0000049071) (Filer)

    6/17/25 3:52:50 PM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Humana upgraded by Raymond James with a new price target

    Raymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $315.00

    5/1/25 7:42:13 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana upgraded by BofA Securities with a new price target

    BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously

    11/6/24 8:21:46 AM ET
    $HUM
    Medical Specialities
    Health Care

    KeyBanc Capital Markets initiated coverage on Humana

    KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight

    10/11/24 7:47:34 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    National Mall of Pickleball Returns for Third Year with Expanded Footprint and New, Central Location

    The National Mall of Pickleball will celebrate America's most accessible sport and the game that serves all in the heart of the National Mall this September The Trust for the National Mall, Humana (NYSE:HUM), and the Humana Foundation announced today that the highly-anticipated National Mall of Pickleball is returning to America's Front Yard, the National Mall, for a third year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625316935/en/ From Friday, September 19 through Sunday, September 21, 2025, the general public can experience a weekend full of pickleball programming, activities, and community with captivating views o

    6/25/25 9:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Launches "Invite" Campaign to Inspire Active Aging Through Pickleball and Community Connection

    Humana Inc. (NYSE:HUM), a leading health and well-being company, is expanding its commitment to senior wellness with the launch of Invite, a new campaign designed to encourage older adults of all fitness levels to stay active, connected and engaged – starting with the fastest-growing sport in America: pickleball. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618737488/en/As part of Humana's new "Invite" campaign, the health and wellness company debuted a television spot featuring senior pickleball athletes extending an open invitation to others to join the fun, stay social, and support their physical and mental well-being. A

    6/18/25 8:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Announces CFO Transition

    Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. "On behalf of the entire Board and management team, I want to extend my thanks to Susan for her leadership as CFO and in prior roles during her nearly two decades at Humana," said Jim Rechtin, Humana's President and Chief Executive Officer. "Susan's contributions spanned across our Medicare, Home So

    12/3/24 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humana and DrFirst Partner on Innovation to Fill Gaps in Care, Improve Outcomes for Patients with Diabetes and Other Chronic Conditions

    Program Designed to Increase Use of Recommended Medication Therapy by Connecting with Providers in Workflow LOUISVILLE, Ky. and ARLINGTON, Va., Aug. 13, 2025 /PRNewswire/ -- Humana Inc. (NYSE:HUM), one of the nation's leading health and well-being companies, and health technology pioneer DrFirst today announced the launch of a program designed to close gaps in care for patients with chronic health conditions like diabetes and cardiovascular disease while helping health care providers take timely, informed action. The first phase of this novel program aims to increase the use of statin therapy among eligible patients, aligning with a key quality metric from the Centers for Medicare & Medicaid

    8/13/25 8:04:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Reports Second Quarter 2025 Financial Results; Raises Full Year 2025 Adjusted EPS and Revenue Guidance

    Reports 2Q25 earnings per share (EPS) of $4.51 on a GAAP basis, Adjusted EPS of $6.27; reports YTD EPS of $14.81 on a GAAP basis, $17.85 on an Adjusted basis 2Q25 Insurance segment benefit ratio of 89.9 percent, in line with the company's previously disclosed expectation of 'approximately 90 percent' Updates FY 2025 GAAP EPS guidance to 'approximately $13.77' from the previous estimate of 'approximately $14.68'; raises Adjusted FY 2025 EPS guidance to 'approximately $17.00', up from the previous 'approximately $16.25' guidance Raises FY 2025 consolidated revenues guidance to 'at least $128 billion' compared to the previous guidance range of $126 billion to $128 billion Affirms

    7/30/25 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Accelerates Efforts to Eliminate Prior Authorization Requirements to Ensure a Faster, More Seamless Process

    New effort will expedite approvals, promote access to care, reduce administrative burdens, and enhance the patient experience Humana Inc., a leading health and well-being company, today announced accelerated efforts to approve care requests as quickly as possible and reduce the administrative burden for physicians associated with prior authorization. These actions will reduce the number of prior authorization requirements and make the process faster and more seamless, while preserving the system of checks and balances that protects patient safety by ensuring the most high-cost, high-risk treatments are reviewed and approved before care is delivered. Today's announcement builds upon the

    7/22/25 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    5/16/25 4:48:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    Mesquita Jorge S. bought $200,066 worth of Humana Common (545 units at $367.09) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/21/24 10:37:23 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Financials

    Live finance-specific insights

    View All

    Humana Reports Second Quarter 2025 Financial Results; Raises Full Year 2025 Adjusted EPS and Revenue Guidance

    Reports 2Q25 earnings per share (EPS) of $4.51 on a GAAP basis, Adjusted EPS of $6.27; reports YTD EPS of $14.81 on a GAAP basis, $17.85 on an Adjusted basis 2Q25 Insurance segment benefit ratio of 89.9 percent, in line with the company's previously disclosed expectation of 'approximately 90 percent' Updates FY 2025 GAAP EPS guidance to 'approximately $13.77' from the previous estimate of 'approximately $14.68'; raises Adjusted FY 2025 EPS guidance to 'approximately $17.00', up from the previous 'approximately $16.25' guidance Raises FY 2025 consolidated revenues guidance to 'at least $128 billion' compared to the previous guidance range of $126 billion to $128 billion Affirms

    7/30/25 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Inc. to Release Second Quarter 2025 Results on July 30, 2025

    Humana will release its 2Q25 financial results, as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on July 30, 2025. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2025. A webcast of the 2Q25 earnings call may be accessed via Humana's Investor Relations page at https://humana.gcs-web.com/. If you anticipate asking a question during the question-and-answer session, please register in advance using this link, https://register-conf.media-server.com/register/BIb5c00e1d1dc14cd7ad2b375d4f1cde21. Upon registration, telephone participants w

    7/9/25 4:15:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance

    Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident

    4/30/25 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/16/24 4:29:43 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/14/24 10:02:59 AM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/13/24 5:06:27 PM ET
    $HUM
    Medical Specialities
    Health Care